Welcome to our dedicated page for WEST PHARMACEUTICAL SERVICES SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on WEST PHARMACEUTICAL SERVICES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into WEST PHARMACEUTICAL SERVICES's regulatory disclosures and financial reporting.
WST notice of proposed sales of Common Stock tied to recent restricted stock vesting events. The filing lists planned dispositions associated with vesting on 04/23/2024, 05/06/2025, 05/07/2025, and 05/04/2026, showing individual lot sizes of 1, 430, 1, and 2,952 shares respectively.
Pucci Paolo reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Paolo Pucci received an equity grant in the form of restricted stock units. He was awarded 791 units of common stock on the reported date, increasing his direct holdings to 11,854.297 shares.
The footnote explains that these restricted stock units will vest in full on the date of the next annual shareholder meeting and will then be distributed under the company’s Deferred Compensation Plan for Outside Directors. This is a compensation-related award rather than an open-market purchase.
WEST PHARMACEUTICAL SERVICES INC director receives stock award. Director Douglas A. Michels acquired 791 shares of common stock as a grant or award, recorded at a price of $0.00 per share, reflecting equity compensation rather than a market purchase.
These shares are in the form of restricted stock units that will vest in full on the date of the next annual shareholder meeting and will be distributable under the company’s Deferred Compensation Plan for Outside Directors. After this grant, Michels directly holds 46,495.55 shares of common stock.
Lockhart Stephen H reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Stephen H. Lockhart received an equity award of 791 shares of common stock. The award is structured as restricted stock units that will vest in full on the date of the next annual shareholder meeting. After this grant, he holds a total of 3,523.2615 shares directly. This is a compensation-related grant, not an open-market purchase or sale.
LAI GOLDMAN MYLA reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Myla Lai-Goldman received 791 shares of Common Stock as a grant. The award was made at no cash cost per share and increased her directly held position to 20,434.587 shares.
According to the footnote, these shares are in the form of restricted stock units that will vest in full on the date of the next annual shareholder meeting and will be distributed under the company’s Deferred Compensation Plan for Outside Directors.
Keller Deborah L reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Deborah L. Keller received a grant of 791 shares of common stock in the form of restricted stock units on May 4, 2026. These restricted stock units will vest in full on the date of the next annual shareholder meeting. After this award, she directly holds 11,560.479 shares of West Pharmaceutical Services common stock.
Joseph Molly reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Molly Joseph received a grant of 791 shares of common stock as restricted stock units. The award was granted at a price of $0.00 per share, reflecting equity compensation rather than an open-market purchase. After this grant, Joseph holds a total of 4,398.187 shares of West Pharmaceutical common stock. According to the disclosure, these restricted stock units will vest in full on the date of the next annual shareholder meeting, at which point they are expected to become fully owned shares, subject to any applicable plan terms.
HAUGEN JANET BRUTSCHEA reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Janet Brutschea Haugen received an equity award in the form of restricted stock units. She was granted 791 shares of common stock at no cash cost, increasing her directly held stake to 2,372.752 shares. The restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributed under the company’s Deferred Compensation Plan for Outside Directors, tying part of her compensation to future company performance.
FRIEL ROBERT F reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Robert F. Friel received a grant of 791 shares of common stock in the form of restricted stock units. The award carried a price of $0.00 per share as it is a compensation grant rather than an open-market purchase.
The restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributed under the Deferred Compensation Plan for Outside Directors. Following this award, Friel directly holds 5,512.97 shares of West Pharmaceutical Services common stock.
Feehery William F reported acquisition or exercise transactions in this Form 4 filing.
WEST PHARMACEUTICAL SERVICES INC director William F. Feehery received an equity award of 791 shares of common stock in the form of restricted stock units. The award was granted at no cash price and increases his directly held position to 32,519.345 shares.
The restricted stock units will vest in full on the date of the next annual shareholder meeting and will then be distributable under the company’s Deferred Compensation Plan for Outside Directors. This reflects routine director compensation rather than an open-market purchase or sale.